Drug Patents owned by G1 Therap

1. Drug name - COSELA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8598186 G1 THERAP CDK inhibitors
Oct, 2031

(9 years from now)

US9957276 G1 THERAP CDK inhibitors
Oct, 2031

(9 years from now)

US10189849 G1 THERAP CDK inhibitors
Oct, 2031

(9 years from now)

US8598197 G1 THERAP CDK inhibitors
Oct, 2031

(9 years from now)

CN104045654A G1 THERAP Cdk Inhibitor
Jun, 2017

(5 years ago)

CN106967074A G1 THERAP Cdk Inhibitor
Mar, 2020

(2 years ago)

CN103429243A G1 THERAP Cdk Inhibitor
Oct, 2031

(9 years from now)

CN106008533B G1 THERAP Cdk Inhibitor
Oct, 2031

(9 years from now)

CN103936745A G1 THERAP Cdk Inhibitor
Oct, 2031

(9 years from now)

CN103936745B G1 THERAP Cdk Inhibitor
Oct, 2031

(9 years from now)

CN106008533A G1 THERAP Cdk Inhibitor
Oct, 2031

(9 years from now)

CN103429243B G1 THERAP Cdk Inhibitor
Oct, 2031

(9 years from now)

IN201303795P4 G1 THERAP Cdk Inhibitors
Oct, 2031

(9 years from now)

IN307331B G1 THERAP Pyrrolopyrimidine Fused Piperazinone Compounds As Cdk Inhibitors
Oct, 2031

(9 years from now)

EP2632467B1 G1 THERAP Cdk Inhibitors
Oct, 2031

(9 years from now)

EP2632467A1 G1 THERAP Cdk Inhibitors
Oct, 2031

(9 years from now)

EP3118203A1 G1 THERAP Cdk Inhibitors
Oct, 2031

(9 years from now)

EP3118203B1 G1 THERAP Cdk Inhibitors
Oct, 2031

(9 years from now)

EP3567042B1 G1 THERAP Cdk Inhibitors
Oct, 2031

(9 years from now)

EP3381920A1 G1 THERAP Cdk Inhibitors
Oct, 2031

(9 years from now)

EP2632467A4 G1 THERAP Cdk Inhibitors
Oct, 2031

(9 years from now)

EP3381920B1 G1 THERAP Cdk Inhibitors
Oct, 2031

(9 years from now)

EP3567042A1 G1 THERAP Cdk Inhibitors
Oct, 2031

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10189850 G1 THERAP CDK inhibitors Oct, 2031

(9 years from now)

US10927120 G1 THERAP CDK inhibitors Oct, 2031

(9 years from now)

US10085992 G1 THERAP Transient protection of normal cells during chemotherapy Mar, 2034

(11 years from now)

US10966984 G1 THERAP Transient protection of normal cells during chemotherapy Mar, 2034

(11 years from now)

US11040042 G1 THERAP Transient protection of normal cells during chemotherapy Mar, 2034

(11 years from now)

US9487530 G1 THERAP Transient protection of normal cells during chemotherapy Mar, 2034

(11 years from now)

Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient

Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a carboplatin and etoposide-containing regimen for extensive-stage small cell lung cancer; A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung cancer; a method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a topotecan-containing regimen for extensive- stage small cell lung cancer

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 300MG BASE/VIAL POWDER;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.